VPM helps facilitate fast track designation for Memo Therapeutics AG’s AntiBKV first-in-class treatment for BK virus infection in renal transplant recipients
VPM contributes to the successful licensure of the novel malaria vaccine R21/Matrix-MTM for first use in Ghana
VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG
Press release on the results of a novel tuberculosis vaccine tested in a large phase III trial against severe respiratory infectious diseases
VPM1002 Vaccination as Prophylaxis Against Severe Respiratory Infectious Diseases Including Covid-19 in the Elderly
The phase I/II clinical trial data with VPM1002BC, a genetically modified bacillus Calmette-Guérin (BCG) strain, has been published in European Urology Oncology. Even three years after the treatment start, almost half of the patients remained recurrence-free. We thank all patients, colleagues, and collaborators for their contributions.
Milestone achieved: end of recruitment for a large African trial against tuberculosis in neonates completed
We are pleased to announce that a major milestone in the pivotal phase III trial (trial name: priMe) of the novel tuberculosis vaccine VPM1002 has been achieved with the end of recruitment of all participants.